On Thursday, May 14, 2026, the NIDA IRP Clinical Program welcomed representatives from the Office of the Lieutenant Governor. Aruna Miller and her staff received a tour of our facilities and learned about the cutting edge research we are conducting in the field of addiction medicine.
Hot Off the Press
Hippocampal output suppresses orbitofrontal cortex schema cell formation
Hot Off the Press – August 21, 2025 Published in Nature Neuroscience by Wenhui Zong and Geoffrey Schoenbaum, et al. of the NIDA IRP Behavioral Neurophysiology Neuroscience Section. Summary The orbitofrontal cortex (OFC) and hippocampus (HC) are both thought to contribute to the construction of cognitive maps and their generalization into schemas, yet the nature… [Read More]
Reviews To Read
Morphinan Alkaloids and Their Transformations: A Historical Perspective of a Century of Opioid Research in Hungary
Reviews To Read – July 2025. Published in International Journal of Molecular Sciences with contributions by Kenner Rice of the NIDA IRP Drug Design and Synthesis Section. The word opium derives from the ancient Greek word ὄπιον (ópion) for the juice of any plant, but today means the air-dried seed capsule latex of Papaver somniferum. Alkaloid… [Read More]
Featured Papers
Chronic delivery of buprenorphine during abstinence decreases incubation of heroin seeking and neuronal activation in medial prefrontal cortex and striatum in male and female rats
Featured Paper of the Month – May 2026
Published in JAMA Network Open by Xiang Xiao and Yihong Yang et al. of the NIDA IRP Magnetic Resonance Imaging and Spectroscopy Section.
Buprenorphine is an FDA-approved medication for opioid addiction, but the brain regions underlying its therapeutic effects are unknown. In this study, we tested whether chronic buprenorphine reduces the time-dependent increase (“incubation”) in heroin seeking during abstinence.
